dbACP: A Comprehensive Database of Anti-Cancer Peptides

dbacp06417

General Description

Peptide name : U3

Source/Organism : Date palm

Linear/Cyclic : Not found

Chirality : Not found

Sequence Information

Sequence : NGSIPATWASL

Peptide length: 11

C-terminal modification: Not found

N-terminal modification : Not found

Non-natural peptide information: None

Activity Information

Assay type : MTT/MTS assay

Assay time : 48h

Activity : IC50 : 561 μM

Cell line : Hep G2

Cancer type : Liver cancer

Other activity : Not found

Physicochemical Properties

Amino acid composition bar chart :

Molecular mass : 1116.2238 Dalton

Aliphatic index : 0.890

Instability index : -17.009

Hydrophobicity (GRAVY) : 0.2909

Isoelectric point : 5.525

Charge (pH 7) : -0.2399

Aromaticity : 0.090

Molar extinction coefficient (cysteine, cystine): (5500, 5500)

Hydrophobic/hydrophilic ratio : 1.75

hydrophobic moment : -0.159

Missing amino acid : C,R,H,Q,M,E,K,F,D,Y,V

Most occurring amino acid : S

Most occurring amino acid frequency : 2

Least occurring amino acid : N

Least occurring amino acid frequency : 1

Structural Information

3D structure :

Secondary structure fraction (Helix, Turn, Sheet): (0.2, 0.4, 0.3)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O

Secondary Structure :

Method Prediction
GOR TTCCCEEEHHH
Chou-Fasman (CF) EECCCCCCCCC
Neural Network (NN) CCCCCCCEHHH
Joint/Consensus CCCCCCCCCCC

Molecular Descriptors and ADMET Properties

Molecular Descriptors: Click here to download

ADMET Properties: Click here to download

Cross Referencing databases

Pubmed Id : 38464729

Uniprot : Not available

PDB : Not available

CancerPPD : Not available

ApIAPDB : Not available

CancerPPD2 ID : Not available

Reference

1 : Baothman O, et al. Prediction of anticancer peptides derived from the true lectins of Phoenix dactylifera and their synergetic effect with mitotane. Front Pharmacol. 2024; 15:1322865. doi: 10.3389/fphar.2024.1322865

Literature

Paper title : Prediction of anticancer peptides derived from the true lectins of Phoenix dactylifera and their synergetic effect with mitotane.

Doi : https://doi.org/10.3389/fphar.2024.1322865

Abstract : Background and aims: Cancer continues to be a significant source of both illness and death on a global scale, traditional medicinal plants continue to serve as a fundamental resource of natural bioactive compounds as an alternative source of remedies. Although there have been numerous studies on the therapeutic role of Phoenix dactylifera, the study of the role of peptides has not been thoroughly investigated. This study aimed to investigate the anticancer activity of lectin peptides from P. dactylifera using in silico and in vivo analysis. Methods: Different computational tools were used to extract and predict anticancer peptides from the true lectins of P. dactylifera. Nine peptides that are bioactive substances have been investigated for their anticancer activity against MCF-7 and T47D (two forms of breast cancer). To counteract the unfavorable effects of mitotane, the most potent peptides (U3 and U7) were combined with it and assessed for anticancer activity against MCF-7 and HepG2. Results: In silico analysis revealed that nine peptides were predicted with anticancer activity. In cell lines, the lowest IC<sub>50</sub> values were measured in U3 and U7 against MCF-7 and T47D cells. U3 or U7 in combination with mitotane demonstrated the lowest IC<sub>50</sub> against MCF-7 and HepG2. The maximum level of cell proliferation inhibition was 22% when U3 (500 µg/mL) and 25 µg/mL mitotane were combined, compared to 41% when 25 µg/mL mitotane was used alone. When mitotane and U3 or U7 were combined, it was shown that these bioactive substances worked synergistically with mitotane to lessen its negative effects. The combination of peptides and mitotane could be regarded as an efficient chemotherapeutic medication having these bioactive properties for treating a variety of tumors while enhancing the reduction of side effects.